# MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5

> **NCT01121237** · — · COMPLETED · sponsor: **Sandoz** · enrollment: 2086 (actual)

## Conditions studied

- Chronic Kidney Disease
- End-stage Renal Disease
- Anaemia

## Interventions

- **DRUG:** Recombinant human erythropoietin alfa (biosimilar)

## Key facts

- **NCT ID:** NCT01121237
- **Lead sponsor:** Sandoz
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 2086 (ACTUAL)
- **Last updated:** 2016-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01121237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01121237, "MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT01121237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*